Mohammad Hossein Salehi1, Massoud Houshmand2, Omid Aryani3, Behnam Kamalidehghan4, Elham Khalili. 1. Dept. of Molecular Genetics, Tarbiat Modares University, Tehran, Iran. 2. Dept. of Medical Genetics, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran. 3. Dept. of Medical Genetics, Special Medical Center, Tehran, Iran. 4. Dept. of Pharmacy, Faculty of Medicine, University of Malaya, Malaysia.
Abstract
BACKGROUND: Friedreich ataxia (FRDA) is an autosomal recessive disorder caused by guanine-adenine-adenine (GAA) triplet expansions in the FXN gene. Its product, frataxin, which severely reduces in FRDA patients, leads to oxidative damage in mitochondria. The purpose of this study was to evaluate the triple nucleotide repeated expansions in Iranian FRDA patients and to elucidate distinguishable FRDA clinical differences in these patients. METHODS: A number of 22 Iranian patients (8 females and 14 males) from 16 unrelated families were studied. DNA was extracted from the peripheral blood of patients. The frequency and length of (GAA)n repeats in intron 1 of the FXN gene were analyzed using long-range PCR. In this study, the clinical criteria of FRDA in our patients and the variability in their clinical signs were also demonstrated. RESULTS: An inverse relationship was observed between GAA repeat size and the age of onset. Although some distinguishable clinical features (such as limb ataxia and lower limb areflexia) were found in our patients, 90-95% of them had extensor plantar response and dysarthria. The results showed only one positive diabetes patient and also different effects on eye movement abnormality among our patients. CONCLUSION: The onset age of symptoms showed a significant inverse correlation with allele size in our patients (P>0.05). Based on comparisons of the clinical data of all patients, clinical presentation of FRDA in Iranian patients did not differ significantly from other FRDA patients previously reported.
BACKGROUND:Friedreich ataxia (FRDA) is an autosomal recessive disorder caused by guanine-adenine-adenine (GAA) triplet expansions in the FXN gene. Its product, frataxin, which severely reduces in FRDApatients, leads to oxidative damage in mitochondria. The purpose of this study was to evaluate the triple nucleotide repeated expansions in Iranian FRDApatients and to elucidate distinguishable FRDA clinical differences in these patients. METHODS: A number of 22 Iranian patients (8 females and 14 males) from 16 unrelated families were studied. DNA was extracted from the peripheral blood of patients. The frequency and length of (GAA)n repeats in intron 1 of the FXN gene were analyzed using long-range PCR. In this study, the clinical criteria of FRDA in our patients and the variability in their clinical signs were also demonstrated. RESULTS: An inverse relationship was observed between GAA repeat size and the age of onset. Although some distinguishable clinical features (such as limb ataxia and lower limb areflexia) were found in our patients, 90-95% of them had extensor plantar response and dysarthria. The results showed only one positive diabetespatient and also different effects on eye movement abnormality among our patients. CONCLUSION: The onset age of symptoms showed a significant inverse correlation with allele size in our patients (P>0.05). Based on comparisons of the clinical data of all patients, clinical presentation of FRDA in Iranian patients did not differ significantly from other FRDApatients previously reported.
Authors: Louise A Corben; Nellie Georgiou-Karistianis; Michael C Fahey; Elsdon Storey; Andrew Churchyard; Malcolm Horne; John L Bradshaw; Martin B Delatycki Journal: Brain Res Bull Date: 2006-06-21 Impact factor: 4.077
Authors: A Dürr; M Cossee; Y Agid; V Campuzano; C Mignard; C Penet; J L Mandel; A Brice; M Koenig Journal: N Engl J Med Date: 1996-10-17 Impact factor: 91.245
Authors: Arnulf H Koeppen; Susan C Michael; Mitchell D Knutson; David J Haile; Jiang Qian; Sonia Levi; Paolo Santambrogio; Michael D Garrick; Jacques B Lamarche Journal: Acta Neuropathol Date: 2007-04-11 Impact factor: 17.088
Authors: L Santoro; G De Michele; A Perretti; C Crisci; S Cocozza; F Cavalcanti; M Ragno; A Monticelli; A Filla; G Caruso Journal: J Neurol Neurosurg Psychiatry Date: 1999-01 Impact factor: 10.154
Authors: L Montermini; E Andermann; M Labuda; A Richter; M Pandolfo; F Cavalcanti; L Pianese; L Iodice; G Farina; A Monticelli; M Turano; A Filla; G De Michele; S Cocozza Journal: Hum Mol Genet Date: 1997-08 Impact factor: 6.150
Authors: A Filla; G De Michele; F Cavalcanti; L Pianese; A Monticelli; G Campanella; S Cocozza Journal: Am J Hum Genet Date: 1996-09 Impact factor: 11.025